|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amgen executive joins Aryx Therapeutics board
- 2 Hours ago
|
|
|
|
FREMONT, Calif. - Biotech drug developer Aryx Therapeutics Inc. on Friday said Amgen executive David Beier has joined its board of directors. Beier handles government relations and corporate communications
|
|
|
|
|
|
|
|
|
|
|
|
|
Oxford BioMedica looking at acquisitions, CEO goes
- 2 Hours ago
|
|
|
|
LONDON (Reuters) - Oxford Biomedica Plc (OXB.L: Quote, Profile, Research) said its chief executive is to leave after just over a month in charge and it was seeking acquisitions to boost its drug pipeline.
|
|
|
|
|
|
|
|
|
|
|
|
|
ImClone updates data from lung cancer trial
- 4 Hours ago
|
|
|
|
BOSTON (Reuters) - ImClone Systems Inc said on Friday that a trial of its cancer drug Erbitux did not significantly improve overall survival in a trial of patients with the most common form of lung cancer.
|
|
|
|
|
|
|
|
|
|
|
|
|
Payday for biotech
- 118 Minutes ago
|
|
|
|
NEW YORK (Fortune) -- Overall, dealmaking may be in a slump, but Big Pharma has been buying up biotech firms at a record pace - it's now the fastest-growing M&A sector, with deal value up 87% this year.
|
|
|
|
|
|
|
|
|
|
|
|
|